Oncolytic virus nabs FDA approval nature.com/articles/d41... Replimune’s vusolimogene oderparepvec (Tudriqev, also known as RP1) has received accelerated approval for use in combination with the PD-1 blocker nivolumab for advanced melanoma. It is the second oncolytic virus to reach the US market

For readers interested in targeted protein degradation, this Perspective in the August issue discusses safety considerations in the development of PROTAC and molecule glue drug candidates that recruit the E3 ligase cereblon www.nature.com/articles/s41... rdcu.be/fzgJJ

Orexin receptor agonist secures landmark narcolepsy approval nature.com/articles/d41... As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists

Artificial intelligence in drug discovery — what it is, where we stand and the path forward nature.com/articles/s41... rdcu.be/fyUFz

Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors - find out more in this news story in our August issue www.nature.com/articles/d41...

Our August issue is live! Read about multispecific T-cell engagers for cancer, the design of small-molecule kinase inhibitors, the evolution of pharmacotherapy for obesity, safety considerations for targeted protein degraders and more here www.nature.com/nrd/volumes/...

For readers interested in drug discovery targeting GPCRs, this Review covers trends in the field: www.nature.com/articles/s41... rdcu.be/fwSqG and this Review covers opportunities from understanding of functional dynamics: www.nature.com/articles/s41... rdcu.be/fwSrj

FDA new drug approvals in Q2 2026 www.nature.com/articles/d41... Q2 2026 saw a rebound for novel FDA drug approvals with a total of 13, also with heavy commercial firepower thanks to products such as the first oral small-molecule GLP-1 receptor agonist

A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails. Find out more in this news story in the July issue www.nature.com/articles/d41...

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development rdcu.be/ftz8C www.nature.com/articles/s41... This new Perspective discusses the value of trial simulations, presents best-practice recommendations and describes case studies of impact

For readers interested in therapeutic strategies for chronic obstructive pulmonary disease (COPD), such as PDE3/4 inhibition - the focus of AstraZeneca's latest potential $2.1 billion deal - here's a review www.nature.com/articles/s41... rdcu.be/fs1jW

CAR T cell therapy for solid cancer scores first approval in China www.nature.com/articles/d41... CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma

Small-molecule drug candidates increasingly have limited aqueous solubility, making oral delivery challenging. This Perspective in the July issue discusses formulation approaches to mitigate solubility and dissolution rate limitations www.nature.com/articles/s41... rdcu.be/fsjUt

Our July issue is live! Read about multispecific biologics, AI in target identification and assessment, CDK inhibitors for treating cancer and the role of formulations in oral delivery of poorly water-soluble drugs here www.nature.com/nrd/volumes/...

Growth in clinical research capability in China and impact on the pharmaceutical sector nature.com/articles/d41... This new article analyses data on the growth in inputs to clinical research capability in China and its impact on outputs such as investigator-initiated trials

This Nature conference will bring together researchers from academia and industry to explore the evolving landscape of cancer therapeutics. Join us in Houston this October for discussions on next‑generation therapies and emerging approaches. go.nature.com/4daqpHm

Multispecific T-cell engagers attract cancer drug developers nature.com/articles/d41... Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors

Can multispecific biologics break the efficacy ceiling? nature.com/articles/d41... A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails

Novel drug targets in 2025 www.nature.com/articles/d41... This new article highlights 11 targets not previously modulated by approved drugs

Antiviral peptide nabs FDA approval for hepatitis delta virus infection www.nature.com/articles/d41... Gilead’s bulevirtide is the first treatment for the potentially fatal infection

For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review nature.com/articles/s41... rdcu.be/fnl3W

A guide to effective drug development through nonprofit models www.nature.com/articles/d41... Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals

Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus www.nature.com/articles/d41... This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures

Better data for better medicines: a path to data-driven medicines regulation www.nature.com/articles/d41... This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven

Towards mRNA therapeutics 2.0 www.nature.com/articles/s41... This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies

Targeting claudins in cancer www.nature.com/articles/s41... rdcu.be/flf2S Claudins, which are key regulators of epithelial function, are emerging as targets in cancer, validated by the approval of a CLDN18.2-targeted drug. This new Review discusses progress in the field #ASCO26

This Review in the May issue discusses how microglia integrate signals from central and peripheral immune cells in neurodegenerative disorders, highlighting therapeutic targets and biomarkers www.nature.com/articles/s41... rdcu.be/fk3uL

Antibody-based extracellular targeted protein degraders that destroy disease-linked proteins in cancer and autoimmunity are advancing in the clinic. Find out more in this news story in our May issue www.nature.com/articles/d41...

FDA approves first-in-class hypertension drug www.nature.com/articles/d41... AstraZeneca’s baxdrostat is the first aldosterone synthase inhibitor to be approved, providing a new way to lower blood pressure. Peak sales >$5 billion are forecasted, but two competitors are close behind